

ESOPHAGOGASTRIC DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON
ROOM: CHURCHILL "B"

SATURDAY APRIL 26TH, 2025 10:15 AM – 11:15 AM

CO-CHAIRS : DR ELENA ELIMOVA, DR GAIL DARLING & DR AAMER MAHMUD
SENIOR INVESTIGATOR: DR CHRIS O'CALLGHAN

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical and translational research, the disease burden associated with esophagogastric malignancies in Canada.
- To identify clinical trial research opportunities in esophagogastric malignancies within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct as these relate to esophagogastric malignancies.
- To integrate and apply new clinical trial methodologies in esophagogastric malignancies in the Canadian Cancer Trials Group research agenda.
- To identify mentoring opportunities for new investigators.

10:15 am	Welcome	
10:15 am	GA.4: A Randomized Phase II Study of Paclitaxel and Ramucriumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma	Dr E Elimova
10:30 am	ES.3 (NEEDS): Neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma versus definitive chemoradiotherapy with salvage surgery as needed	Dr R Wong Dr J Lukovic
10:45 am	New Abbvie Concept: Phase 2 or 3 trial	Dr E Elimova
11:00 am	TORO: Toronto Resection of Oligomets Trial	Dr. E Wakeman Dr. G. Darling
11:10 am	NCTN Esophagogastric Task Force Update	Dr E Elimova Dr A Mahmud
11:15 am	Meeting Adjourned	





Canadian Cancer Society
Société canadienne du cancer

CCTG is a CCS national program.